Peptide Receptor Radionucleotide Therapy for Unresectable Paediatric Head and Neck Paraganglioma in Aotearoa New Zealand.

Head and neck paragangliomas present incidentally or with signs of mass effect. Approximately 30%-40% are hereditary, which typically present at a younger age. Given their proximity to vital structures, they are often inoperable, and alternative treatment options have significant side effects. We present a case of a paediatric patient with a glomus jugulare paraganglioma who received peptide receptor radionucleotide therapy (PRRT), a targeted molecular therapy. We observed a good molecular response stable disease at 12-month follow-up and radiologically stable disease at 15 months posttreatment. PRRT is not currently a widely accessible treatment option, and the literature reports a reasonable disease response in treatment of head and neck paraganglioma.